Afatinib in Previously Treated ESCC With EGFR Overexpression or EGFR Amplification (ESCC-A01)

Esophageal Squamous Cell Carcinoma Clinical Trial

Official title:

Phase 2 Study of Afatinib in Previously Treated Recurrent or Metastasic Esophageal Squamous Cell Carcinoma With EGFR Overexpression or EGFR Amplification (ESCC-A01)

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03940976
• Other study ID #: ESCC-A01
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: April 28, 2019
• Est. completion date: May 1, 2020

Study information

• Verified date: June 2019
• Source: Peking University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a phase 2 trial investigating the effect and safety of afatinib in previously treated recurrent or metastasic esophageal squamous cell carcinoma with EGFR overexpression or EGFR amplification.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 40
• Est. completion date: May 1, 2020
• Est. primary completion date: January 1, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

1. Having signed informed consent.

2. Age 18 to 70 years old.

3. Histologically confirmed esophageal squamous carcinoma

4. Immunohistochemistry confirmed EGFR(3+) or EGFR-FISH-amplification or next generation sequencing confirmed EGFR-amplification.

5. Computed tomography (CT) or magnetic resonance imaging (MRI) confirmed unresectable metastasic or recurrent ESCC.

6. Refractory or intolerant to at least one regimen.

7. Measurable disease according to the Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 criteria(diameter of the lesion should be more than 10mm by spiral CT or MRI, more than 20mm by common CT, the date of image should be less than 21 days before enrollment)

8. Life expectancy of =3 month

9. Eastern Cooperative Oncology Group (ECOG) 0-2

10. WBC>3,000/mm3, absolute neutrophil count =1500/mm3, platelet>100,000/mm3, Hb>9g/dl,Bilirubin level < 1.5 times ULN,Serum creatinine <1.5 times ULN,ALT and AST<2.5 times ULN ,AKP < 2.5 times ULN ,(=5 times ULN in patients with liver metastases)(within 7 days before enrollment)

11. No sever complication, such as active gastrointestinal bleeding, perforation, jaundice, obstruction, non-cancerous fever>38?.

12. Good compliance

Exclusion Criteria:

1. Contraindications of afatinib.

2. Unable to take afatinib orally because of esophageal stenosis.

3. Currently receiving other effective regimens.

4. Previous anticipate other clinical trial within 4 weeks before entering this study.

5. No measurable lesions, eg. pleural fluid and ascites.

6. With other malignancy within 5 year, except non-melanoma skin cancer and cervical carcinoma in situ.

7. Heart failure or other sever organ dysfunction, eg. coronary artery disease, myocardial infarction within the last 6 months.

8. Mentally abnormal or disable cognition,including central nervous system (CNS) metastasis.

9. HIV infection, active hepatitis B or hepatitis C.

10. Unstable systemic diseases such as poorly controlled diabetes.

11. Interstitial lung disease, such as interstitial pneumonia, pulmonary fibrosis, or evidence of interstitial lung disease showed in X-ray/CT.

12. Keratitis, ulcerative keratitis or severe dry eye syndrome. Known hypersensitivity to study drug.

13. Pregnancy or lactation period.

14. Active severe infection within 14 days.

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Squamous Cell
• Esophageal Squamous Cell Carcinoma

Intervention

Drug:
• Afatinib
Afatinib is orally administered at 40mg Qd of each 28 day cycle.

Locations

Country	Name	City	State
China	Peking University Cancer Hospital and Institute	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Peking University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Objective response rate	Percentage of patients who achieve partial response (PR) or complete response (CR) based on Response Evaluation Criteria In Solid Tumors (RECIST).	From date of first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months.
Secondary	Incidence of Treatment-Related Adverse Events	Number of adverse events of afatinib in patients with ESCC.	Until 30 days after the last treatment
Secondary	Disease control rate	Percentage of patients who achieve partial response (PR) or complete response (CR) or stable disease (SD) based on Response Evaluation Criteria In Solid Tumors (RECIST).	From date of first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months.
Secondary	Progression free survival	Measure of time from study treatment to disease progression or death	Up to 2 years
Secondary	Overall survival	Measure of time from study treatment to patient's death or lost to follow-up.	Up to 2 years